Alnylam Pharmaceuticals has exceeded a $50 billion market capitalization following a strong launch of its rare heart disease medication Amvuttra. The RNA interference therapy showed impressive sales growth, doubling year-over-year revenues to $492 million in its first full quarter. Adoption among transthyretin amyloidosis cardiomyopathy patients has been robust, with broad coverage across major health systems and payers. Executives emphasize continued efforts to position Amvuttra as a leader in this underserved market segment.